Natera
Precision-medicine diagnostics company using cell-free DNA testing across oncology, women's health, and organ health. Its portfolio contains diagnostic assays, not therapeutic drugs.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
NA · Recruiting · Single Gene NIPT
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNA · Recruiting · Breast Neoplasms
Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)NA · Not Yet Recruiting · Kidney Transplant
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal CancerNA · Not Yet Recruiting · Gastric-Esophageal Cancer
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NA · Not Yet Recruiting · NSCLC (Advanced Non-small Cell Lung Cancer)
Signatera Assessment in Early-Stage Endometrial CancerNA · Not Yet Recruiting · Endometrial Cancer
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/natera/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.